Actively Recruiting

Age: 6Years +
All Genders
NCT06683092

Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

Led by Boston Children's Hospital · Updated on 2025-11-03

200

Participants Needed

18

Research Sites

161 weeks

Total Duration

On this page

Sponsors

B

Boston Children's Hospital

Lead Sponsor

C

Cystic Fibrosis Foundation

Collaborating Sponsor

AI-Summary

What this Trial Is About

RETRIAL is a multi-site observational study of people with Cystic Fibrosis (PWCF) ages 6 and up starting the new triple-therapy modulator (vanzacaftor/tezacaftor/deutivacaftor (VTD)), after having experienced neuropsychiatric events and/or liver injury while taking elexacaftor/tezacaftor/ivacaftor (ETI) that resulted in a modification or discontinuation of standard ETI dosing.

CONDITIONS

Official Title

Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

Who Can Participate

Age: 6Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

RETRIAL-Mental Health:

  • PWCF age 6 years and up (if age is < 12 years old, the PWCF's caregiver will complete daily diaries and surveys; see "Caregiver Participant Inclusion Criteria" below)

  • Eligible for VTD and intending to take it

  • Experienced new or worsening mental health symptoms after initiating ETI, which led to one of the following changes in treatment to currently taking:

    1. No modulators
    2. A modulator other than ETI
    3. A flipped dose of ETI
    4. A reduced dose of ETI
  • Willing to delay first VTD dose for short period of time to complete the Baseline assessments

  • Has access to a smart device (phone, tablet, etc.) capable of receiving messages with survey links

  • Is English-speaking.

RETRIAL-LIVER:

  • A person with CF age 6 years and up

  • Eligible for VTD and intending to take it

  • Experienced drug-induced liver injury (as defined by local care team) after initiating ETI, which led to one of the following changes in treatment to currently taking:

    1. no modulators; or
    2. a modulator other than ETI; or
    3. a reduced or altered dose of ETI;
  • Willing to delay first VTD dose for short period of time to complete the Baseline assessments

  • Has access to a smart device (phone, tablet, etc.) capable of receiving messages with survey links

  • Is English-speaking.

Not Eligible

You will not qualify if you...

RETRIAL-Mental Health:

  • Cannot access VTD
  • Currently, or prior history of, taking VTD
  • Unable or unwilling to follow protocol
  • If <12 years old, having another <12-year-old person in the same household consented into the study
  • Is actively listed on any transplant list, or within 3 months post-transplant surgery
  • Is currently pregnant (test not required)
  • Anticipated change in CF Care Centers in the next 6 months
  • Any situation that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.

RETRIAL-LIVER:

  • Cannot access VTD
  • Currently, or prior history of, taking VTD
  • Unable or unwilling to follow protocol
  • If <12 years old, having another <12-year-old person in the same household consented into the study
  • Any severe, decompensated liver disease (e.g. Child-Pugh, Class C)
  • Is actively listed on any transplant list, or within 3 months post-transplant surgery (any organ), or history of liver transplant
  • Is currently pregnant (test not required)
  • Anticipated change in CF Care Centers in the next 6 months
  • Any situation that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.

Caregiver Participant:

Inclusion Criteria:

  • Is a primary, daily caregiver of a person with CF under the age of 12 enrolled in the study
  • Has access to smart device (phone, tablet, etc.) capable of receiving messages with survey links
  • Is able to read and complete surveys and Daily Diary in English.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 18 locations

1

University of Alabama at Birmingham

Birmingham, Alabama, United States, 35233

Actively Recruiting

2

Children's Hospital Colorado

Aurora, Colorado, United States, 80045

Actively Recruiting

3

National Jewish Health

Denver, Colorado, United States, 80206

Actively Recruiting

4

Nemours Children's

Wilmington, Delaware, United States, 19803

Actively Recruiting

5

Nemours Children's

Jacksonville, Florida, United States, 32207

Actively Recruiting

6

Nemours Children's

Orlando, Florida, United States, 32827

Actively Recruiting

7

Nemours Children's

Pensacola, Florida, United States, 32514

Actively Recruiting

8

Emory University

Atlanta, Georgia, United States, 30322

Actively Recruiting

9

Indiana University

Bloomington, Indiana, United States, 47405

Actively Recruiting

10

Kansas University Medical Center

Kansas City, Kansas, United States, 66160

Actively Recruiting

11

Johns Hopkins University

Baltimore, Maryland, United States, 21287

Actively Recruiting

12

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Not Yet Recruiting

13

Boston Children's Hospital

Boston, Massachusetts, United States, 02215

Actively Recruiting

14

University of Michigan

Ann Arbor, Michigan, United States, 48109

Actively Recruiting

15

Washington University at St. Louis

St Louis, Missouri, United States, 63130

Not Yet Recruiting

16

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States, 15224

Actively Recruiting

17

University of Texas Southwestern Medical Center

Dallas, Texas, United States, 75235

Actively Recruiting

18

Seattle Children's Hospital

Seattle, Washington, United States, 98105

Actively Recruiting

Loading map...

Research Team

E

Evelyn Bord, BS

CONTACT

C

Callie Bacon, MPH

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL) | DecenTrialz